Revance Therapeutics (RVNC) Misses Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
August 9, 2022 4:05 PM EDTPDUFA date of September 8, 2022 for DaxibotulinumtoxinA for Injection in glabellar lines Reinspection of manufacturing facility completed as part of Class II BLA resubmission for DaxibotulinumtoxinA for Injection in glabellar lines Second quarter total revenue of $28.4 million, with RHA® Collection revenue of $25.5 million Aesthetic accounts across products and services totaled over 4,000 at quarter-end Revance launches RHA® Redensity for the treatment of moderate to severe perioral rhytids (lip lines) Conference call and webcast today at 4:30 p.m. ET.
NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics,... More
